Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E- EPS (ttm)-0.08 Insider Own0.10% Shs Outstand227.65M Perf Week6.76%
Market Cap29.36B Forward P/E15.10 EPS next Y8.54 Insider Trans-1.01% Shs Float221.81M Perf Month9.78%
Income-15.80M PEG- EPS next Q1.74 Inst Own96.20% Short Float1.77% Perf Quarter5.36%
Sales3.75B P/S7.84 EPS this Y23.50% Inst Trans0.82% Short Ratio2.92 Perf Half Y19.07%
Book/sh39.39 P/B3.27 EPS next Y18.16% ROA-0.70% Target Price158.00 Perf Year-10.40%
Cash/sh5.17 P/C24.95 EPS next 5Y17.23% ROE-1.10% 52W Range102.10 - 144.91 Perf YTD7.86%
Dividend- P/FCF171.32 EPS past 5Y11.10% ROI4.70% 52W High-6.60% Beta0.83
Dividend %- Quick Ratio2.30 Sales past 5Y25.60% Gross Margin87.00% 52W Low32.56% ATR2.90
Employees2525 Current Ratio2.70 Sales Q/Q14.60% Oper. Margin1.50% RSI (14)72.13 Volatility2.50% 2.17%
OptionableYes Debt/Eq0.37 EPS Q/Q-380.20% Profit Margin-2.70% Rel Volume4.56 Prev Close128.99
ShortableYes LT Debt/Eq0.33 EarningsOct 25 BMO Payout- Avg Volume1.35M Price135.35
Recom1.80 SMA2011.95% SMA509.51% SMA20012.74% Volume755,802 Change4.93%
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-26-18 08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
07:09AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
07:02AM  [$$] Alexion Pharmaceuticals to Buy Syntimmune for Up to $1.2 Billion The Wall Street Journal
06:51AM  Alexion Pharmaceuticals to buy Syntimmune for up to $1.2 billion, including potential milestone payments MarketWatch
06:42AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
06:30AM  Alexion to Acquire Syntimmune Business Wire
Sep-25-18 06:05PM  Alexion's Soliris Successful in Phase III Study for NMOSD Zacks
04:30PM  Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
08:50AM  Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher Zacks
08:00AM  Today's Research Reports on Trending Tickers: Akcea Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-24-18 11:30AM  Stocks - Pandora Gains in Pre-market; Tesla, Comcast Tumble Investing.com +5.34%
09:38AM  Stocks Slump As Trade War Intensifies; 3 Med Stocks Rally, Tilray Tumbles Investor's Business Daily
07:45AM  Stocks making the biggest move premarket: CMCSA, FOXA, P, SIRI, ALXN & more CNBC
06:30AM  Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Sep-07-18 04:30PM  Alexion to Present at Morgan Stanleys 16th Annual Global Healthcare Conference Business Wire
Sep-05-18 07:40AM  Nielsen names David Anderson CFO, effective Sept. 10 MarketWatch
Aug-29-18 04:30PM  Alexion to Present at Citis 13th Annual Biotech Conference Business Wire
Aug-22-18 11:43AM  Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco Zacks
Aug-21-18 11:15AM  Alexion's BLA for ALXN1210 Gets Priority Review From FDA Zacks
Aug-20-18 09:37AM  Stocks Jump At Starting Bell As This Dow Stock Retakes Buy Point Investor's Business Daily
06:30AM  FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US Business Wire
Aug-10-18 01:56PM  Biotech ETFs in Focus on String of Q2 Earnings Beat Zacks
Aug-08-18 08:15AM  Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-06-18 09:30AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
Aug-02-18 01:19AM  Edited Transcript of ALXN earnings conference call or presentation 26-Jul-18 12:00pm GMT Thomson Reuters StreetEvents -5.25%
Aug-01-18 12:14PM  5 Stocks Trading Near 52-Week High With More Upside in Store InvestorPlace
09:39AM  5 Stocks Trading Near 52-Week High With More Upside in Store Zacks
Jul-26-18 02:42PM  Vertex and Alexion Are Schooling Big Biotech Bloomberg
10:26AM  Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up Zacks
09:23AM  Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates Zacks
07:44AM  Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates Zacks
06:59AM  Alexion: 2Q Earnings Snapshot Associated Press
06:30AM  Alexion Reports Second Quarter 2018 Results Business Wire
Jul-25-18 03:45PM  6 Stocks to Buy for Trade War Protection Kiplinger
10:27AM  Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More Zacks
Jul-23-18 11:29AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
Jul-19-18 09:50AM  ALXN or RGNX: Which Is the Better Value Stock Right Now? Zacks
09:45AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
09:21AM  Karyopharm Initiates NDA Submission Process for Selinexor Zacks
Jul-18-18 03:39AM  J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised) Zacks
Jul-17-18 04:04PM  J&J's (JNJ) Phase III Study for Invokana Halted Earlier Zacks
09:40AM  J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised) Zacks
08:33AM  Roche's Flu Drug Meets Primary Endpoint in Phase III Study Zacks
08:03AM  Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert Zacks
Jul-16-18 08:31AM  Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population Zacks
Jul-09-18 06:00AM  4 Biotechs on Verge of Big Breakouts Investopedia
Jul-05-18 08:37AM  3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas InvestorPlace
Jun-28-18 04:30PM  Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018 Business Wire
06:30AM  Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU) Business Wire
Jun-26-18 02:00PM  Is Alexion Pharmaceuticals Inc (NASDAQ:ALXN) A Financially Sound Company? Simply Wall St.
09:30AM  ALXN vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Jun-21-18 11:49AM  3 Big Biotechs That Can Beat the Market Investopedia
Jun-20-18 05:03PM  Alexion (ALXN) Submits Application for ALXN1210 with FDA Zacks
08:32AM  Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash Zacks
07:52AM  5 Stocks That Are Screaming Buys Right Now TheStreet.com
05:56AM  Future home of PTC, Alexion could sell for $450M American City Business Journals
Jun-19-18 04:21PM  Why This Biotech Company Could Shock 2019 Sales Expectations Investor's Business Daily
06:30AM  Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S. Business Wire
Jun-15-18 10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
Jun-14-18 07:30AM  Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA) Business Wire
Jun-13-18 10:34AM  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod Zacks
07:20AM  Wired News Alexion Pharma and Complement Pharma Inked Deal to Co-develop Preclinical C6 Complement Inhibitor CP010 ACCESSWIRE
Jun-12-18 09:16AM  Alexion-Complement Pharma Tie Up to Treat Neuro Disorders Zacks
Jun-11-18 07:30AM  Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders Business Wire
07:10AM  Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks ACCESSWIRE
Jun-05-18 04:45PM  Why Alexion's Blockbuster Franchise Is Safe From Copycats For Now Investor's Business Daily
04:30PM  Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
May-30-18 08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
07:30AM  Wired News Alexion Pharma Announced Acceptance of Offer by Wilson Therapeutics ACCESSWIRE
May-28-18 02:41AM  Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report? Zacks
May-25-18 09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
01:05AM  Alexion Offer for Wilson Therapeutics Accepted Business Wire
May-09-18 04:44AM  Mass. had the fastest-growing economy in the Northeast for 2017 American City Business Journals
May-08-18 04:30PM  Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference Business Wire
May-06-18 02:11PM  Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More Benzinga
May-02-18 03:01PM  Edited Transcript of ALXN earnings conference call or presentation 26-Apr-18 2:00pm GMT Thomson Reuters StreetEvents
09:23AM  Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1 Zacks
May-01-18 03:00PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Apr-27-18 08:39AM  Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5% Zacks
Apr-26-18 04:56PM  Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris Investor's Business Daily +14.50%
04:33PM  Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today Motley Fool
04:03PM  Here's Why Alexion Pharmaceuticals Is Surging Today Motley Fool
11:41AM  Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress American City Business Journals
10:39AM  Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up Zacks
10:05AM  Drug Makers: A Dose of Robust Earnings Barrons.com
08:11AM  Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates Zacks
07:28AM  Alexion: 1Q Earnings Snapshot Associated Press
06:30AM  Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study Business Wire
Apr-25-18 01:25PM  3 Charts That Suggest Biotech Stocks Are Headed Lower Investopedia
10:56AM  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX Zacks
07:30AM  [$$] New Biotech Grabs Series A for Rare Disease Treatments The Wall Street Journal
04:29AM  [$$] A frenzy of dealmaking in pharma points to cost pressure Financial Times
Apr-24-18 08:46AM  Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season Zacks
Apr-23-18 05:08PM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
06:49AM  Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-20-18 05:14PM  Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris Investor's Business Daily
04:52PM  Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab) Business Wire
02:00PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-18-18 12:56PM  NYSE trader: Here's why stocks are up and headline risk is down Yahoo Finance Video
10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clancy Paul JEVP, Chief Financial OfficerJul 10Sale131.115,241687,14893,309Jul 12 05:23 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale118.531,466173,76531,909Jun 12 04:52 PM
Goff BrianEVP & Chief Commercial OfficerJun 08Sale118.531,645194,98236,257Jun 12 04:51 PM
LAW ANNE-MARIEEVP and CHROJun 08Sale118.531,862220,70329,450Jun 12 04:51 PM
ORLOFF JOHN JEVP, Research & DevelopmentJun 08Sale118.532,115250,69131,790Jun 12 04:51 PM
COUGHLIN CHRISTOPHER JDirectorApr 30Buy120.7910,0001,207,90026,333May 02 05:42 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale118.6145453,84949,140Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale118.6168681,36642,787Mar 01 05:25 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale120.7224429,45649,594Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale120.72939113,35643,473Mar 01 05:25 PM
Goff BrianEVP & Chief Commercial OfficerFeb 08Sale116.311,651192,02828,962Feb 08 07:17 PM
Moriarty John BEVP & General CounselFeb 08Sale115.703,363389,09974,537Feb 08 07:16 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale116.314,787556,77644,412Feb 08 07:16 PM
Franchini Indrani LallEVP, Chief Compliance OfficerFeb 08Sale116.311,459169,69625,031Feb 08 07:16 PM
Clancy Paul JEVP, Chief Financial OfficerFeb 08Sale116.316,079707,04889,014Feb 08 07:17 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale116.311,774206,33449,838Feb 08 07:17 PM
HANTSON LUDWIGCEOFeb 08Sale116.3113,2451,540,526118,180Feb 08 07:16 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale117.2665576,80532,635Feb 07 06:36 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale117.262,119248,47420,210Feb 07 06:35 PM
Moriarty John BEVP & General CounselFeb 05Sale117.261,261147,86549,911Feb 07 06:35 PM
HANTSON LUDWIGCEOJan 02Sale121.632,553310,52136,172Jan 04 06:33 PM
Wagner Heidi LSVP, Global Government AffairsOct 02Sale140.0012016,80033,290Oct 04 05:25 PM